Phase III
A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
Podcasting since 2024 • 11 episodes
Phase III
Latest Episodes
NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek
Drone-deliveries of radioactive medicines and diagnostics to Australia's far-flung towns. Radiopharmaceuticals matched with genetic information to tailor precisely the right dose and isotope to a person's cancer. Pan-cancer drugs that fix many ...
•
Season 2
•
Episode 6
•
34:16
NUKED: Patent puzzles, with FB Rice
The rule of thumb in biotech is that it costs around $1 billion to bring a new therapy from lab to market. Protecting that investment is the patent system. But what if part of your product is not made by your contract manufacturer, but by the p...
•
Season 2
•
Episode 5
•
25:20
NUKED: Australia the nuclear power, with entX and Cyclowest
Can Australia create a mine to lab to bedside production line for radiopharmaceutical medicine? It has the reactor, biotechs and the hospitals to do that last two, and even has a growing pool of expertise to run these. What it doesn...
•
Season 2
•
Episode 4
•
29:58
NUKED: The IP game, with Clarity Pharmaceuticals and Radiopharm Theranostics
The question we are dancing around in episode 3 of NUKED is whether locking down isotopes supply chains are really the only way to play the radiopharmaceutical game. We ask Clarity Pharmaceutical executive chair Alan Taylor and <...
•
Season 2
•
Episode 3
•
26:25
NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals
In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment sched...
•
Season 2
•
Episode 2
•
29:47